CRISPR/Cas9/sgRNA-mediated targeted gene modification confirms the cause-effect relationship between gyrA mutation and quinolone resistance in Escherichia coli

FEMS Microbiology Letters
Haixiang QiuChengming Wang

Abstract

Quinolones are broad-spectrum antibiotics that have been used for decades in treating bacterial infections in humans and animals, and subsequently bacterial resistance to these agents has increased. While studies indicated the relationship between gyrA mutations and bacterial resistance to quinolones, CRISPR/Cas9 was used in this study to investigate causal role of gyrA mutation in the quinolone resistance. In this study, 818 clinical Escherichia coli isolates were analyzed for gyrA mutations and their resistance to quinolones. The CRISPR/Cas9 system was used to generate gyrA mutations in quinolone-susceptible E. coli ATCC 25922, and quinolone-resistant clinical E. coli. The antimicrobial resistance prevalence rate in E. coli against nalidixic acid, ciprofloxacin and enrofloxacin was 77.1% (631/818), 51.1% (418/818) and 49.8% (407/818), respectively. The gyrA mutations were identified in nucleotide positions 248, 255, 259, 260, 261, 273 and 300, and mutations at positions 248 and 259 resulting in amino acid changes at positions 83 and 87 were associated with quinolone resistance. Double-site amino acid mutations increase resistance to quinolones. The gyrA mutations causing changes at amino acids 83 and 87 reversed the features ...Continue Reading

References

Nov 30, 1989·The American Journal of Medicine·L M FisherM E Cullen
Dec 20, 1999·Drugs·D C Hooper
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D C Hooper
Apr 11, 2001·Emerging Infectious Diseases·D C Hooper
Jun 21, 2005·Emerging Infectious Diseases·Morten HelmsUNKNOWN DT104 Study Group
May 24, 2006·Microbes and Infection·Geovana Brenner MichaelStefan Schwarz
Jul 14, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John T BrooksLaurence Slutsker
Sep 15, 2009·Current Topics in Medicinal Chemistry·Karl DrlicaXilin Zhao
Jan 24, 2013·Molecular Systems Biology·Kevin M Esvelt, Harris H Wang
Jan 31, 2013·Nature Biotechnology·Wenyan JiangLuciano A Marraffini
Sep 5, 2013·Molecular Systems Biology·Peter J EnyeartAndrew D Ellington
May 21, 2014·Antimicrobial Agents and Chemotherapy·Nadine HändelBenno H ter Kuile
Oct 11, 2014·Foodborne Pathogens and Disease·Minyoung LeeYeonhee Lee
Mar 24, 2017·FEMS Microbiology Reviews·Diarmaid Hughes, Dan I Andersson

❮ Previous
Next ❯

Citations

Feb 6, 2019·The Journal of Microbiology·Enrique Jesús Delgado-SuárezMaría Salud Rubio-Lozano
May 6, 2020·Infection and Drug Resistance·Peng WanZhenling Zeng
Mar 19, 2020·Frontiers in Microbiology·Bumjoon KimSang Jun Lee
Feb 28, 2019·Journal of Advanced Research·Zong-Yen WuPo-Yu Liu
Jul 3, 2021·Antibiotics·Manuel González de AledoMaría Tomás

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPRi Screens for Antibiotics

The CRISPR-Cas system is a gene editing technique that can be used for high-throughput genome-wide screens to identify modes of actions of novel antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
Eric BatardFrançoise Ballereau
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
S ChaniotakiWHONET Study Group
© 2022 Meta ULC. All rights reserved